Clinical Trials Logo
  1. Home
  2. HER-2 Protein Overexpression
  3. NCT06055153

DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With HER2 IHC2+/3+ ESCC

HER-2 Protein Overexpression Clinical Trial

Official title:
DV Combined With PD-1 and Platinum-based First-line Treatment in Patients With Locally Advanced or Metastatic HER2 IHC2+/3+ Esophageal Squamous Cell Carcinoma

Clinical Trial Summary

This is a single-arm, exploratory clinical study.

Clinical Trial Description

This is a single-arm, exploratory clinical study. Aim to explore the safety and efficacy of Vedicetuzumab combined with an immune checkpoint inhibitor (carrellizumab) and platinum-based first-line treatment for locally advanced/metastatic HER2 overexpression (IHC 2+/3+) esophageal squamous cell carcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06055153
Study type Interventional
Source Changhai Hospital
Contact Xianbao Zhan, Doctor
Phone 862131162338
Email zhanxianbao@126.com
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date September 30, 2023
Completion date April 30, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05511844 - Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors Phase 1
Terminated NCT02840110 - Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product
Recruiting NCT04692831 - Testing a New Imaging Agent to Identify Cancer Phase 1
Withdrawn NCT04464967 - Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers Phase 1/Phase 2
Terminated NCT03680560 - Study of ACTR T Cell Product in Combination With Trastuzumab in Subjects With HER2-Positive Advanced Solid Tumor Cancers Phase 1
Completed NCT03613168 - Trastuzumab in HER2-positive Biliary Tract Cancer Phase 2
Withdrawn NCT04602117 - ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer Phase 1
Recruiting NCT05480384 - Adjuvant Trastuzumab Deruxtecan (Enhertu) & Nivolumab For Patients Who Are Disease Free After Completion of Trimodality Treatment For HER-2+ Cancers of Esophagus & Gastroesophageal Junction Phase 2
Enrolling by invitation NCT05904730 - Phase I Clinical Trials Investigating the Potential Efficacy of Axitinib in Patients With a BRCA 1/2 Mutations Phase 1
Not yet recruiting NCT06187506 - Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer Phase 2
Terminated NCT03630809 - Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 Phase 2
Recruiting NCT05170256 - Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients Phase 2
Active, not recruiting NCT04660929 - CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors Phase 1
Recruiting NCT04995003 - HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma Phase 1
Suspended NCT04650451 - Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors Phase 1
Not yet recruiting NCT04215159 - Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor Phase 2
Recruiting NCT05868226 - PRE-I-SPY Phase I/Ib Oncology Platform Program Phase 1
Not yet recruiting NCT04179656 - The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor Phase 2